United Therapeutics Corporation

    UTHR ·NASDAQ ·Pharmaceutical Preparations ·Inc. in DE
    Loading chart...
    Track markets on TradingView

    Loading financial statements...

    Financial statements

    data from SEC XBRL filings. Values are as-reported; restatements supersede originals.

    showing loading…

    Loading holders...

    Held by

    holders ( registered funds via N-PORT, institutional investors via 13F). Showing top by dollar value.

    Holder Type ETF MF Position ($) % of holder Δ % of holder Holder AUM

    Recent insider activity

    Last 90 days. Open-market trades (purchases & sales) by directors, officers, and 10%+ owners. 5 transactions across 2 insiders. Net: -48,000 shares, -$27,280,632.

    Date Insider Role Action Shares Price Value
    2026-04-29 ROTHBLATT MARTINE A Chairperson & CEO Sell -9,500 ×9 $571.22 -$5,426,598
    2026-04-28 ROTHBLATT MARTINE A Chairperson & CEO Sell -9,500 ×8 $568.04 -$5,396,353
    2026-04-27 ROTHBLATT MARTINE A Chairperson & CEO Sell -9,500 ×8 $568.81 -$5,403,684
    2026-04-27 EDGEMOND JAMES CFO AND TREASURER Sell -10,000 ×7 $568.83 -$5,688,319
    2026-04-24 ROTHBLATT MARTINE A Chairperson & CEO Sell -9,500 ×7 $564.81 -$5,365,678

    Source: SEC Form 4 filings.

    Next expected filings

    • ~2026-07-29 10-Q expected by 2026-08-07 (in 89 days)
    • ~2026-10-28 10-Q expected by 2026-11-06 (in 180 days)
    • ~2027-02-24 10-K expected by 2027-04-13 (in 299 days)
    • ~2027-04-29 10-Q expected by 2027-05-08 (in 363 days)

    Predicted from historical filing cadence; not an SEC commitment.

    Recent SEC filings

    • 2026-03-30 8-K Other Events; Financial Statements and Exhibits
    • 2026-03-09 8-K Material Agreement Entered; Regulation FD Disclosure; Financial Statements and Exhibits
    • 2026-02-25 10-K Annual Report
    • 2026-02-25 8-K Earnings Release; Financial Statements and Exhibits
    • 2026-01-22 8-K Officer/Director Change; Bylaws/Articles Amended; Regulation FD Disclosure; Financial Statements and Exhibits
    • 2025-10-29 10-Q Quarterly Report
    • 2025-10-29 8-K Earnings Release; Financial Statements and Exhibits
    • 2025-09-02 8-K Other Events; Financial Statements and Exhibits
    • 2025-08-01 8-K Material Agreement Entered; Regulation FD Disclosure; Financial Statements and Exhibits
    • 2025-07-30 10-Q Quarterly Report
    • 2025-07-30 8-K Earnings Release; Financial Statements and Exhibits
    • 2025-06-27 8-K Officer/Director Change; Shareholder Vote Results; Financial Statements and Exhibits
    • 2025-04-30 10-Q Quarterly Report
    • 2025-04-30 8-K Earnings Release; Financial Statements and Exhibits
    • 2025-04-28 8-K Material Agreement Entered; Material Agreement Terminated; Material Financial Obligation; Financial Statements and Exhibits